CSL Signs licensing agreement with Arcturus Therapeutics
CSL Limited recently announces that its subsidiary, CSL Seqirus, has entered into a collaboration and license agreement with Arcturus Therapeutics Holdings Inc (“Arcturus Therapeutics”) to access their late stage self-amplifying mRNA (sa-mRNA) vaccine platform technology. Arcturus Therapeutics is currently developing next generation mRNA vaccines. It has developed a COVID-19 vaccine candidate and has recently reported […]
